Podium to Practice: Chicago 2025 – GI: ATOMIC

Podium to Practice: Chicago 2025 – GI: ATOMIC

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Sharlene Gill

Icon Chair Speaker

Speakers

Dr. Rachel Goodwin

Dr. Florian Lordick

Studies / Trials Discussed

LBA1 – Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).

Studies/trials discussed:

LBA1 – Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).
Tagged